Sumant Ramachandra, M.D., Ph.D., has served as a member of our board of directors since October 2024. Since November 2021, he has served as the Chief Executive Officer of ImmPACT Bio USA, Inc., a wholly-owned subsidiary of Lyell. He also served as a member of the board of directors of ImmPACT from December 2021 to October 2024, when ImmPACT was acquired by Lyell. Prior to joining ImmPACT, Dr. Ramachandra was most recently Chief Science, Technology and Medical Officer for Baxter International since June 2017. In addition to these responsibilities, he was appointed President of Baxter Pharmaceuticals in mid-2019 and was appointed as Baxter’s Chair for the Global Inclusion Council focused on inclusion and diversity. Prior to Baxter, he worked with Pfizer, most recently as Senior Vice President, Head of Research & Development, Pfizer Essential Health. He served as Chief Scientific Officer at Hospira from 2008 to 2015 prior to Pfizer’s acquisition of Hospira in 2015. Earlier in his career, Dr. Ramachandra worked with Pfizer and Merck & Co. in various senior-level oncology global product development, medical affairs and business development and licensing roles and as a clinical pharmacologist. Before entering the industry in 2000, he was an intern and resident physician, medical services, at Massachusetts General Hospital, Harvard Medical School.
Dr. Ramachandra completed his undergraduate degree in biochemistry, graduate degree (Ph.D.) in experimental pathology in the study of chronic lymphocytic leukemia and his medical degree (M.D.) at Rutgers University. In addition, he earned his M.B.A. at The Wharton School at the University of Pennsylvania.
What is Sumant Ramachandra's net worth?
The estimated net worth of Sumant Ramachandra is at least $254.60 thousand as of March 21st, 2025. Ramachandra owns 10,000 shares of Lyell Immunopharma stock worth more than $254,600 as of December 5th. This net worth estimate does not reflect any other assets that Ramachandra may own. Learn More about Sumant Ramachandra's net worth.
How do I contact Sumant Ramachandra?
Has Sumant Ramachandra been buying or selling shares of Lyell Immunopharma?
Sumant Ramachandra has not been actively trading shares of Lyell Immunopharma within the last three months. Most recently, on Friday, March 21st, Sumant Ramachandra bought 10,000 shares of Lyell Immunopharma stock. The stock was acquired at an average cost of $11.60 per share, with a total value of $116,000.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company's stock, valued at $116,000. Learn More on Sumant Ramachandra's trading history.
Who are Lyell Immunopharma's active insiders?
Are insiders buying or selling shares of Lyell Immunopharma?
In the last twelve months, Lyell Immunopharma insiders bought shares 5 times. They purchased a total of 38,432 shares worth more than $449,508.40. In the last twelve months, insiders at the sold shares 12 times. They sold a total of 2,400 shares worth more than $30,063.50. The most recent insider tranaction occured on November, 10th when CEO Lynn Seely sold 412 shares worth more than $6,637.32. Insiders at Lyell Immunopharma own 22.3% of the company.
Learn More about insider trades at Lyell Immunopharma. Information on this page was last updated on 11/10/2025.
